Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to ease hidden pain after keyhole surgery

NCT ID NCT07525986

Recruiting now Symptom relief Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called anrikefon for treating internal pain after laparoscopic (keyhole) surgery. It is given through a pump that lets patients control their own pain relief. The trial includes 140 adults having colorectal surgery. The goal is to see if anrikefon provides better pain control with fewer side effects than standard painkillers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
anrikefon
What this could lead to
If it works, this could provide a better way to manage internal pain after laparoscopic surgery, reducing reliance on opioids and their side effects.
What could go wrong
This is a small, early-phase pilot study (140 people). The drug may not work better than existing options, or could have unexpected side effects. Results may not apply to all surgeries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANRIKEFON are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Visceral Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANRIKEFON LAPAROSCOPIC SURGERY PATIENT-CONTROLLED INTRAVENOUS ANALGESIA VISCERAL PAIN, POSTOPERATIVE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University First Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.